| 31.73 2.37 (8.07%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 43.21 |
1-year : | 50.47 |
| Resists | First : | 37 |
Second : | 43.21 |
| Pivot price | 29.81 |
|||
| Supports | First : | 30.06 |
Second : | 25.77 |
| MAs | MA(5) : | 28.54 |
MA(20) : | 29.41 |
| MA(100) : | 24.94 |
MA(250) : | 179.55  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.5 |
D(3) : | 23.8 |
| RSI | RSI(14): 56.9 |
|||
| 52-week | High : | 910 | Low : | 15.1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ QNCX ] has closed below upper band by 19.1%. Bollinger Bands are 9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 37.06 - 37.24 | 37.24 - 37.4 |
| Low: | 29.48 - 29.65 | 29.65 - 29.8 |
| Close: | 31.43 - 31.73 | 31.73 - 32 |
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Fri, 09 Oct 2026
A $116 million cash balance on June 30, 2026, is expected to fund IRulya's operations through 2028. - Stock Titan
Fri, 09 Oct 2026
Raymond James Starts Quince Therapeutics Inc. (QNCX) at Outperform - StreetInsider
Thu, 08 Oct 2026
Quince Therapeutics, Inc. (QNCX) options chain - Yahoo Finance Australia
Tue, 06 Oct 2026
Quince Therapeutics stock wins approval for major share issuance - AD HOC NEWS
Tue, 06 Oct 2026
QNCX: Five proposals passed preliminarily; the adjournment proposal was not presented - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 34.9 (%) |
| Shares Short | 60 (K) |
| Shares Short P.Month | 51 (K) |
| EPS | -210.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -34.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.6 % |
| Return on Equity (ttm) | -153.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -59.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.16 |
| PEG Ratio | 0 |
| Price to Book value | -0.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|